BARLOW JAMES F 4

What Happened James F. Barlow, a director of Arcturus Therapeutics Holdings, was granted a derivative award for 15,000 shares on June 5, 2026. The Form 4 lists the transaction as an award/acquisition at $0.00 per share (reported as a derivative instrument). According to the filing footnote, this is the reporting person’s 2026 annual board grant.

Key Details

• Transaction date: 2026-06-05; reported on Form 4 filed 2026-06-15 (filing appears late relative to the typical 2-business-day Form 4 deadline).
• Instrument: Derivative award (footnote identifies it as shares underlying an option).
• Quantity: 15,000 shares; price shown on the form: $0.00 (standard reporting format for Awards/Grants).
• Vesting: Shares underlying the option vest monthly over a one-year period from the grant date (per footnote).
• Shares owned after transaction: Not disclosed in the provided summary.

Context This is an annual director compensation grant, not an open-market buy or sale. Such awards are common for board members and do not by themselves indicate an immediate purchase or sale of stock. The delayed filing reduces the speed at which the market and investors learn of the grant.